Clinical economics review: Helicobacter pylori-associated peptic ulcer disease.
The high prevalence and chronic nature of peptic ulcer disease have traditionally resulted in a major economic burden on health care systems. In 1991, for example, peptic ulcer disease was estimated to account for over one-third of all National Health Service expenditure on gastrointestinal diseases. It is now well established that elimination of Helicobacter pylori can lead to a dramatic reduction in gastroduodenal ulcer relapse, with obvious clinical benefits. This review considers the economic implications of the use of H. pylori eradication therapy in peptic ulcer disease.
Bodger
K
K
Division of Medicine, St James's University Hospital, Leeds, UK.
Daly
M J
MJ
Heatley
R V
RV
D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D019468:Disease Management; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy / Q000191:economics*; D016480:Helicobacter pylori; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy / Q000191:economics* / Q000382:microbiology